Recognized by Business Insider in 2025 as “one of the top 100 early-stage investors,” Dr. Alucozai has experience translating exceptional science and technology into scalable commercial ventures. Alongside his experience as a founder and operator, he has actively invested in over 50 startups across North America and Europe. He has often been the first investor to back high-growth companies like Seqera Labs. Milad began his career as a neuroscientist at the intersection of bioengineering, computational biology, and machine learning, where he commercialized platforms designed to deliver promising medicines to patients more efficiently and safely. His focus as an investor has been to accelerate the journey of groundbreaking discoveries from the lab to the market, particularly in the life sciences sector and related computational fields.
Milad is a co-founder and General Partner at Pamir Ventures, an early-stage venture firm that invests in technical pioneers developing B2B companies utilizing AI in antiquated industries. He is also a co-founder of Revalia Bio, which aims to establish a human-centric infrastructure for drug discovery and development. By using non-transplantable human organs donated for research, Revalia offers the scientific community unparalleled insights into patient biology, ultimately aiding in the creation of improved treatments and cures. In 2024, he partnered with The Wyss Institute at Harvard University to launch and co-host the popular “Code to Cure” series, which explores the convergence of AI, biology, and healthcare. He also provides his expertise as a Senior Fellow in Healthcare Engineering at the Regenstrief Center.
Throughout his operating and investing career, Milad has played a crucial role in helping founders secure hundreds of millions in capital and facilitating over $1 billion in startup-pharma partnerships. Often serving as the first investor, he guides companies, particularly in business development for high-growth, venture-backed startups. His previous roles include supporting business development at Accenture, Absci, Bit Bio, Numerate, Mekonos, and AstraZeneca. Through Digitalis Commons, he was an Expert in Residence in support of the Advanced Research Projects Agency for Health (ARPA-H), where he aided the US government and ARPA-H mission to enable transformative biomedical and health breakthroughs, providing health solutions through $1.5 billion in non-dilutive investments. Previously, as Head of Bio and Deep Tech at BoxOne Ventures, his investments established the firm as a leading player in North America’s venture capital landscape. He also served as a Venture Partner at Entrepreneur First, a globally recognized talent investor backed by notable figures like Patrick and John Collison of Stripe and Reid Hoffman of LinkedIn, with a portfolio exceeding $10 billion in value.
Milad was a National Science Foundation Scholar and Macklin Fellow at Johns Hopkins Medicine. He graduated Phi Beta Kappa with a degree in Neuroscience from Purdue University’s Honors Program, earned a master’s in Immunology and Public Health as a George J. Mitchell Scholar, and holds a doctorate from the Richard M. Fairbanks School of Public Health.
At the Wyss Institute, Milad is a member of the Wyss Mentor Hive who specializes in commercializing transformative technologies and fostering startup ecosystems.
The Wyss Mentor Hive is a mentoring program that invites investors and business professionals with significant early stage translational experience, clinical and regulatory experts in driving therapeutic and device development, and serial entrepreneurs with a track record of success to work closely with Wyss entrepreneur teams on startup formation and technology commercialization. Mentors provide feedback to founders and entrepreneurs, while also demonstrating commitment and leadership in the Wyss innovation community.